Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nathanael Gray
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
C4 Therapuetics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see attached.
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
Project Narrative Lung cancer is the leading cause of cancer death world-wide. The purpose of our integrated research program is to discover information and create pilot molecules that will lead to new lung cancer treatments. During the past five years, we have advanced lung cancer treatments by promoting three new lung cancer clinical trials, one of which has led to approval of a new drug. During the next five years, we plan to build on this effort and further advance new lung cancer treatments.
Filed on September 15, 2017.
Tell us what you know about Nathanael Gray's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Nathanael Gray”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Syros Pharmaceuticals | >$600,000 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $80,000 - $99,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $80,000 - $99,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Syros Pharmaceuticals | $60,000 - $79,999 |
| Nathanael Gray | New York University School of Medicine | Conflict of Interest | Syros | $100,000 - $149,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Petra Pharmaceuticals | $60,000 - $79,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapuetics | $80,000 - $99,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Syros Pharmaceuticals | $60,000 - $79,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.